Maegim

Stock search

Search by company name, 6-digit code, or Korean initials (e.g. ㅅㅅㅈㅈ)

☆한국어

KAINOS MEDICINE, INC.

카이노스메드284620KOSDAQSector: Pharma & Biotech
₩1,0870.00%Market cap ₩36.0BAs of Sep 1, 2026 close · updated once daily
Market cap
₩36.0B
#1306 in KOSDAQ
Loss
PER not computable
31.35x
Sector median 1.61x
0.0%
Sector median 0.0%
Trading halted — grade display suspended

This stock is under a trading halt per KRX disclosure. Grade display resumes once trading resumes.

See withholding criteria →View source filing (DART) ↗

This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1-year closing price

Loading closing price history…
 
Low ₩1,087High ₩1,087
Latest close
Price change by period
1W
0.00%
1M
0.00%
3M
0.00%
1Y
0.00%

As of the Sep 1, 2026 close · updated once daily · a factual record computed from closing prices only; dividends are not included, and this is not a buy or sell signal.

1

Financial strength

31.4/100
How much debt does it carry relative to equity?
43.8%
Sector median 51.6%
Sector lowhighTop 40.7% in sector
Can it cover what's due within a year?
218.9%
Sector median 191.7%
Sector lowhighTop 44.3% in sector
How much of revenue becomes profit?
-549.6%
Sector median -2.4%
Sector lowhighBottom 8.4% in sector
How much did it earn on its own capital?
-614.0%
Sector median -4.5%
Sector lowhighBottom 2.2% in sector

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

84.7/100
How much did revenue grow in a year?
98.5%
Sector median 6.4%
Sector lowhighTop 9.8% in sector
Has it grown steadily over three years?
108.1%
Sector median 4.9%
Sector lowhighTop 5.2% in sector
Did core profits grow in a year?
47.8%
Sector median 3.6%
Sector lowhighTop 20.2% in sector
Are core profits higher than three years ago?
60.1%
Sector median 3.5%
Sector lowhighTop 26.1% in sector

Financial trend

Revenue

Growth & margin

Revenue growth Operating margin

Year over year — alongside the sector median

This stock Sector median

A factual chart of confirmed annual results from annual reports — the same source as the grading indicators. Not a buy or sell signal.

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

10.6/100
Is the price expensive relative to earnings?
Loss-making (P/E not computable)
Sector median P/E of profitable peers 16.3x · 58% loss-making
Sector lowhighBottom 15.6% in sector
Is the price expensive relative to book value?
31.35x
Sector median 1.61x
Sector lowhighBottom 5.5% in sector

Valuation uses the Sep 1, 2026 close and market cap

4

Shareholder Return

Single-indicator axis37.5/100
Does the company actually pay dividends?
0.0%
Sector median 0.0%
Sector lowhighBottom 37.5% in sector

Dividends & treasury shares

Treasury shares (FY2025)
375,585 shares (1.1% of shares issued)

Source: annual report (DART) — dividend allocation & total shares

Source filing: annual report (consolidated) — view original ↗

Financial checklist

Based on the FY2025 annual report · year-over-year comparison · determined on Sep 2, 2026

Of 9 items: 5 met · 4 not met · 0 not computable

Not metMetNot computable

Positive net income
Whether net income (attributable to owners where available) is above zero.
Not met
-₩7B
Positive operating cash flow
Whether cash flow from operations is above zero.
Not met
-₩5.9B
Return on assets up
Whether net income over beginning total assets rose from the prior year.
Not met
-58.1% → -65.6%
Operating cash flow exceeds net income
Whether operating cash flow is greater than net income.
Met
-₩5.9B vs -₩7B
Liabilities-to-assets ratio down
Whether total liabilities as a share of total assets fell from the prior year.
Met
45.3% → 30.4%
Current ratio up
Whether current assets over current liabilities rose from the prior year.
Met
98.0% → 218.9%
Shares outstanding not increased
Whether common shares issued did not increase from the prior year. Increases from bonus issues and stock dividends are also counted.
Not met
28,180,793 → 33,086,953
Operating margin up
Whether operating income over revenue rose from the prior year.
Met
-2088.2% → -549.6%
Asset turnover up
Whether revenue over beginning total assets rose from the prior year.
Met
0.03x → 0.11x

A record of facts determined by fixed rules from the financial statements in the latest annual report. Not used in grading, and not a buy or sell signal. Source filing: annual report (consolidated) — view original ↗

Grade change history

Jul 23, 2026D→F

Methodology version change (v2.0 applied)

Jul 15, 2026C→DVersion v1.1

Methodology version change (v1.1 applied)

Jul 15, 2026CVersion v1

First calculation

Grade changes are a factual record produced from public data by a fixed formula; they do not signal future changes.

Disclosure & financial badges

Factual records determined from public filings and periodic reports by fixed rules — not buy/sell signals.

Negative-evidence group (dilution, loss, dispute)Mixed interpretationPositive-evidence group (shareholder return)Dots classify the disclosure type by the direction of research evidence — not an assessment or investment judgment about this company.

Disclosure event history

Large paid-in capital increase resolved

Disclosed a paid-in capital increase (제3자배정증자) issuing 4,906,160 new shares, equal to 17.4% of shares outstanding before the increase (filed 2025-04-01). View filing ↗

Financial fact combinations

Operating losses for 3 consecutive fiscal years

Recorded operating losses in three consecutive fiscal years, FY2023–FY2025 (per annual reports).

Determined as of 2026-09-02

Recent filings for this stock

Last 120 days · monitored filing types only
Periodic report filedAug 14, 2026Source ↗
Periodic report filedMay 15, 2026Source ↗

View in the filings calendar →